Silence Therapeutics to discuss Phase 2 SANRECO trial topline results for divesiran in polycythemia vera

SLN•2026-08-09

Trial results not yet disclosed

Results have not yet been presented. The announcement did not describe the trial outcome or indicate whether divesiran met key study objectives.

Conference call scheduled for Aug. 10

Silence Therapeutics scheduled an Aug. 10, 2026 conference call to discuss topline Phase 2 SANRECO results for divesiran in polycythemia vera. The company said the call and webcast will include the topline readout.

Silence Therapeutics to discuss Phase 2 SANRECO trial topline results for divesiran in polycythemia vera

Trial results not yet disclosed

Conference call scheduled for Aug. 10

Related News

Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers

Iran's Revolutionary Guard says re-opening Strait of Hormuz does not depend on talks with Oman

U.S. Senate passes short-term funding bill to avert federal shutdown before election

Nasdaq Trade Halt Continues <MCTA.O> Reason Not Available at 03:28 AM

Delta flight makes emergency landing in Atlanta